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Background: FFA4 is a receptor for long-chain fatty acids and is considered a novel target for metabolic diseases.
Results: Combinations of molecular modeling, receptor mutagenesis, and ligand structure-activity relationships defined the
binding pocket.
Conclusion: Fatty acid and synthetic agonists share an overlapping binding site.
Significance: The validated homology model will assist the search for novel ligands.
The long-chain fatty acid receptor FFA4 (previously GPR120)
is receiving substantial interest as a novel target for the treat-
ment of metabolic and inflammatory disease. This study exam-
ines for the first time the detailedmode of binding of both long-
chain fatty acid and synthetic agonist ligands at FFA4 by
integrating molecular modeling, receptor mutagenesis, and
ligand structure-activity relationship approaches in an iterative
format. In doing so, residues required for binding of fatty acid
and synthetic agonists to FFA4 have been identified. This has
allowed for the refinement of awell validatedmodel of themode
of ligand-FFA4 interaction that will be invaluable in the identi-
fication of novel ligands and the future development of this
receptor as a therapeutic target. The model reliably predicted
the effects of substituent variations on agonist potency, and it
was also able to predict the qualitative effect of binding site
mutations in the majority of cases.
FFA4 (previously designated GPR120) is a 7-transmembrane
G protein-coupled receptor (GPCR)4 activated by long-chain
fatty acids (LCFAs) that has been receiving increasing interest
in recent years as a novel therapeutic target for the treatment of
metabolic conditions, including diabetes (1, 2). This is in large
part based on studies demonstrating that activation of FFA4 by
LCFA ligands results in a number of potentially beneficial bio-
logical effects, including stimulation of secretion of glucagon-
like peptide-1 from enteroendocrine cells (3), inhibition of
ghrelin secretion (4), stimulation of glucose uptake by adi-
pocytes (5), promotion of pancreatic -cell survival (6), and
inhibition of the release of pro-inflammatory cytokines from
macrophages that, in turn, improve systemic insulin sensitivity
(5). In addition, genetic studies have shown that disruption of
FFA4 function in bothmice and humans is linked to obesity (7).
Taken together, these observations suggest that FFA4 agonists
represent an exciting new possibility for the treatment of met-
abolic disease.
Despite the recent interest in FFA4, its development as a
therapeutic target has been hindered by a lack of available
ligands and, in particular, a lack of ligands with suitable selec-
tivity for FFA4 over FFA1, the other GPCR activated by LCFAs.
Indeed, beyond the use of LCFAs that activate FFA1 and FFA4
with very similar potency, much of the early work on FFA4
utilized the compound GW9508, despite the fact that this
ligand has only modest potency at FFA4 (1–5M) and is100-
fold more potent at FFA1 (8). Early attempts to identify novel
FFA4-selective agonists yielded only modest success, with all
compounds described displaying low potency and/or very lim-
ited selectivity for FFA4 over FFA1 (9, 10). However, the recent
description of ortho-biphenylmethoxyphenylpropionic acid
derivatives as selective FFA4 agonists, as exemplified by the
most potent and selective compound TUG-891, has provided a
means to selectively probe the function of FFA4 (11). Indeed,
we have recently used TUG-891 to explore in detail the in vitro
pharmacology of FFA4 to begin to define the therapeutic
potential of this receptor (12).
Although TUG-891 currently represents the best available
FFA4-selective ligand, this compound still possesses relatively
modest potency and high lipophilicity (ClogP 5.8), and it has
been shown tohave limited selectivity for themouse ortholog of
FFA4 overmouse FFA1 (12). Considering these factors, there is
a clear need to identify novel FFA4 agonists. Structure-based
ligand design represents one approach that might be used to
identify ligands for this receptor. However, although this
approach has been successfully used for other GPCRs (13, 14),
the lack of atomic level structural information on FFA4 is cur-
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rently a restriction. Although there have been great advances in
recent years within the field of GPCR structural biology (15), it
still remains impractical to obtain high resolution structures for
receptors on demand. Instead, structure-based drug design
must utilize homologymodeling of the receptor and its binding
site linked to validation by detailed receptor mutagenesis and
functional studies.
In this study, a combination of molecular modeling,
mutagenesis, and ligand structure-activity relationship (SAR)
studies have been employed, through an iterative approach, to
define the orthosteric binding site of FFA4. Through this, we
have identified key residues within FFA4 involved in binding of
the LCFA, -linolenic acid (aLA), the previously studied FFA1/
FFA4 agonist GW9508, as well as TUG-891. We demonstrate
key differences in the interaction of each ligand with FFA4 and
provide rationale for the high potency of the structural scaffold
of TUG-891. Furthermore, examining SAR variations of this
ortho-biphenyl scaffold has identified key residues in FFA4
responsible for the preference for the terminal methyl substit-
uent present in TUG-891. Taken together, combining these
approaches has allowed us to develop a well validated model of
ligand interaction with FFA4 that will be useful in the future
identification of novel ligands for this receptor.
EXPERIMENTAL PROCEDURES
Materials—Compounds TUG-670, TUG-804, TUG-826,
TUG-827, TUG-839, TUG-853, TUG-854, TUG-856, and
TUG-891 were synthesized as described previously (11). aLA
and GW9508 (4-[[(3-phenoxyphenyl)methyl]amino]benze-
nepropanoic acid) were purchased from Sigma. Tissue culture
reagents were from Invitrogen.Molecular biology enzymes and
reagents were from Promega. All other experimental reagents
were from Sigma.
TUG-909 (3-(4-((4-fluoro-3-methyl-[1,1-biphenyl]-2-yl)-
methoxy)phenyl)propanoic acid) was synthesized as follows. A
flask containing m-tolylboronic acid (35 mg, 0.25 mmol),
methyl 3-(4-((2-bromo-5-fluorobenzyl)-oxy)-phenyl)propano-
ate (10) (85 mg, 0.23 mmol), potassium carbonate (38 mg, 0.28
mmol), acetonitrile (1.75 ml), water (0.18 ml), and Pd(PPh3)4
(14 mg, 0.012 mmol) under argon was heated at 80 °C for 20 h.
The reaction was cooled to room temperature, concentrated,
diluted with ethyl acetate, and filtered. The filtrate was washed
with water and brine, dried (Na2SO4), and concentrated. The
residue was purified by flash chromatography (SiO2, EtOAc/
petroleum ether, 1:9) to give 64 mg (73%) of the methyl ester of
TUG-909 as a colorless oil: Rf 0.50 (EtOAc/petroleum ether,
1:2); 1HNMR (400MHz, CDCl3)  7.34 (dd, J 9.7, 2.7Hz, 1H),
7.31–7.24 (m, 2H), 7.19–7.02 (m, 6H), 6.80–6.74 (m, 2H), 4.89
(s, 2H), 3.65 (s, 3H), 2.87 (t, J 7.8 Hz, 2H), 2.58 (t, J 7.8 Hz,
2H), 2.35 (s, 3H); 13CNMR (100MHz, CDCl3)  173.5, 162.4 (d,
JCF  246.1 Hz), 157.0, 139.6, 138.2, 136.8 (d, JCF  7.5 Hz),
133.2, 131.6 (d, JCF  8.0 Hz), 130.1, 129.4, 128.4 (d, JCF  4.3
Hz), 126.3, 115.4 (d, JCF 22.4 Hz), 115.1, 114.8 (d, JCF 21.1
Hz), 67.8, 51.7, 36.1, 31.1, 30.2, 21.6.
The methyl ester of TUG-909 (20 mg, 0.053 mmol) in THF
(0.27ml) was added to LiOHH2O (7.0mg, 0.16mmol) in water
(0.32 ml). The reaction mixture was stirred at room tempera-
ture for 4 h, then acidified with 1 M HCl solution until pH 1,
and extracted with ethyl acetate. The combined organic phase
was washed with brine, dried (Na2SO4), and concentrated to
give 19 mg (98%) of TUG-909 as a white solid: mp 94–95 °C;
Rf 0.10 (EtOAc/petroleum ether, 1:2); 1H NMR (400 MHz,
DMSO-d6)  12.17 (br s, 1H), 7.42–7.15 (m, 7H), 7.10 (d, J 8.1
Hz, 2H), 6.78 (d, J 8.3Hz, 2H), 4.89 (s, 2H), 2.78–2.71 (m, 2H),
2.58 to 2.41 (m, 2H), 2.28 (s, 3H); 13C NMR (100MHz, DMSO-
d6)  172.2, 161.4 (d, JCF  244.0 Hz), 156.2, 138.8, 137.8 (d,
JCF  3.0 Hz), 136.6 (d, JCF  7.6 Hz), 133.4, 132.9, 131.8 (d,
JCF  8.1 Hz), 129.7, 129.2, 128.2, 128.1 126.0, 115.6 (d, JCF 
21.9 Hz), 114.9 (d, JCF 20.9 Hz), 114.53, 67.1, 35.3, 29.4, 20.9;
HRMS calculated for C23H21FO3Na (M  Na) was 387.1367
and found was 387.1378.
Homology Modeling—The sequences of the short isoform of
human FFA4 and the nanobody-stabilized 2-adrenoreceptor
(Protein Data Bank 3P0G) (16) were aligned manually. Homol-
ogy models of FFA4 were constructed using the Prime module
implemented in the Schro¨dinger suite 2012 (17). The FFA4
model was built using default settings, preprocessed using the
OPLS-2005 force field, added hydrogen atoms, and assigned
partial charges. Hydrogen bond assignment was done at pH 7.4
using PROPKA (18). Restrained minimization was performed
until heavy atoms converged to root mean square deviation 
0.3 Å using the OPLS-2005 force field. Loop refinement was
performed using Prime’s loop refinement module (17). For
short loops, the default sampling rate was chosen, whereas the
highest sampling rate was used for loops with more than eight
amino acid residues. Variable dielectric surface-generalized
Born model was selected as the solvent model. Side chains
within 7 Å of the loop were energy-minimized with the energy
cutoff at 10 kcal/mol. Mutations were introduced in the hFFA4
model in Maestro, and rotamers were adjusted manually to
minimize side-chain clashes. The mutant models were prepro-
cessed and restrained minimized using the OPLS-2005 force
field in the Protein Preparation Wizard.
Ligand Preparation and Docking—All ligands were con-
verted to three-dimensional structures in Maestro. Macro-
model was used for energy minimization of ligands using the
OPLS-2005 force field (19). Ligands were prepared using Lig-
Prep (39). Ionization states were generated using Epik at pH
7.0 1.0, and low energy ring conformations were restricted to
one per ligand (20). Induced-fit docking studies were per-
formed using the IFD 2006 protocol as implemented in
Schro¨dinger suite 2013-1 (21). The docking box was placed to
include Arg-992.64, Phe-1153.29, Phe-2115.42, Trp-2776.48, and
Phe-3047.36. Hydrogen bond constraints were set between the
carboxylate of the ligand and Arg-992.64 and applied in both
docking stages. Ligand conformational sampling was per-
formed using default settings. Initial Glide docking was per-
formed using standard settings, and the maximum number of
poses per ligand was restricted to 15. Prime was used to refine
residues within 5.0 Å of ligand poses. Re-docking was per-
formed in Glide using the extra precisionmode for the 10 high-
est ranking protein-ligand complex structures generated in the
initial docking, which was within 30.0 kcal/mol of the lowest
energy protein-ligand complex structure.
Calculation of Ligand Binding Energies—Molecularmechan-
ics with generalized Born and surface area solvation (MM-
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GBSA) simulations were used to calculate ligand-binding
energy (Gbind) (22). Calculations were performed for all the
docking poses resulting from induced-fit docking. Complexes
were taken from separated ligand and protein structures; the
variable dielectric surface-generalized Born solvation method
was used, and the protein flexibility region was restricted to 4.0
Å from ligand. In sampling, only side chains were minimized,
and constraints were applied on flexible residues to restrict
them from deviating too much from their initial position.
Plasmids and Mutagenesis—Plasmids encoding the short
isoform of human FFA4 fused at its C terminus to enhanced
yellow fluorescent protein (eYFP) and containing an N-termi-
nal FLAG epitope tag and -arrestin-2 fused to Renilla lucifer-
ase (Rluc)were as described previously (11, 12).Mutationswere
introduced into the FFA4 sequence using the QuikChange
method (Stratagene), and in all cases the presence of the muta-
tion was verified through sequencing.
Generation of Stable Inducible Cell Lines—Stable inducible
293 cell lines were generated for either wild type or mutant
FFA4-eYFP constructs using the Flp-InTM T-RExTM system
(Invitrogen). Briefly, Flp-InTM T-RExTM 293 cells were
co-transfected with the desired FFA4-eYFP construct and the
pOG44 plasmid encoding the Flp recombinase enzyme. This
allows for polyclonal selection of cells using hygromycin B to gen-
erate cell lineswith inducible expression of the desired receptor in
response to the antibiotic doxycycline. Once generated, receptor
expression and doxycycline sensitivity were confirmed by fluores-
cencemicroscopy to detect the C-terminal eYFP tag.
-Arrestin-2 Interaction Assay—HEK293T cells were main-
tained in Dulbecco’s modified Eagle’s medium supplemented
with 10% heat-inactivated FBS at 37 °C and 5% CO2. Transfec-
tions were carried out with polyethyleneimine, and experi-
ments were conducted 48 h post-transfection according to a
previously described protocol (12). Briefly, HEK293T cells were
co-transfectedwith FLAG-FFA4-eYFP (or appropriatemutant)
and-arrestin-2-Rluc plasmids in a ratio of 4:1. 24 h post-trans-
fection, cells were subcultured into poly-D-lysine-coated white
96-well tissue culture plates and maintained for a further 24 h
prior to the experiment. To conduct the experiments, cells were
first washed and then incubated at 37 °C for 30 min in Hanks’
balanced salt solution. The Rluc substrate coelenterazine h was
added to a final concentration of 2.5 M before a further incu-
bation for 10min at 37 °C. Test compounds were then added at
the specified concentration, and cells were incubated for a final
5-min period prior to measuring luminescent emission at 530
and 490 nm using a PheraStar FS plate reader (BMG Lab Tech)
fitted with a BRET1 optic module. The 530/490 emission ratio
was calculated and corrected for the ratio obtained in cells
transfected with only the -arrestin-2-Rluc plasmid to obtain
the “net BRET” signal. To compare the magnitude of signal
across FFA4mutants, net BRETvalueswere normalized against
the signal obtained from wild type FFA4 treated with 100 M
aLA.
Total and Cell Surface Receptor Expression Measurements—
HEK293T cells co-transfected with FLAG-FFA4-eYFP (or
mutant) and-arrestin-2-Rluc plasmids in a 4:1 ratio were sub-
cultured 24 h after transfection into poly-D-lysine-coated black
96-well tissue culture plates with clear bottoms. After 24 h, cells
were incubated with an anti-FLAG monoclonal primary anti-
body diluted in culture medium for 30 min at 37 °C. Cells were
washed with phosphate-buffered saline (PBS) and then incu-
bated for 30 min with a combination of Hoechst 33342 and a
horseradish peroxidase-conjugated anti-mouse IgG secondary
antibody. Cells were then washed three times with PBS before
reading both eYFP (excitation 500 nm and emission 535 nm)
and Hoechst (excitation 355 nm and emission 460 nm) on a
PolarStar Omega plate reader (BMGLabTech). Cells were then
washed a final timewith PBS before incubation in the dark with
the horseradish peroxidase SureBlueTM TMB substrate (KPL,
Inc.). Absorbance at 620 nm was then measured on a PolarStar
Omega plate reader. To obtain total expression, the eYFP fluo-
rescence was corrected for cell number based on the Hoechst
fluorescence. Surface expression was reported as the 620 nm
absorbance corrected for cell number based on Hoechst fluo-
rescence. In both cases, all values were expressed as a percent-
age of the signal obtained from wild type FLAG-FFA4-eYFP-
transfected cells.
Ca2 Mobilization Assays—Flp-InTM T-RExTM 293 cells
engineered to express the desired form of FFA4 were plated
50,000 cells/well in black 96-well plates with clear bottoms.
Cells were then treated with 100 ng/ml doxycycline to induce
receptor expression and maintained overnight at 37 °C and 5%
CO2 prior to their use. For the assay, cells were first pre-labeled
for 45 min with the calcium-sensitive dye Fura2-AM, then
washed, and maintained in Hanks’ balanced salt solution.
Fura-2 fluorescent emission at 510 nm resulting from 340 or
380 nm of excitation was then monitored using a Flexstation II
plate reader (Molecular Devices). Basal fluorescence was mea-
sured for 16 s; test compounds were then added, and fluores-
cence was measured for an additional 74 s. The background
subtracted peak 340/380 ratio obtained following compound
addition was then used to plot concentration-response data.
Data Analysis and Curve Fitting—All data presented repre-
sent the means  S.E. of at least three independent experi-
ments.Data analysis and curve fittingwere carried out using the
GraphPad Prism software package version 5.0b. Concentra-
tion-response data were plotted on a log axis, where the
untreated vehicle control condition was plotted at 1 log unit
lower than the lowest test concentration of ligand and fitted to
a three-parameter sigmoidal concentration-response curve.
Statistical analysis was carried out using one-way analysis of
variance and Bonferroni post hoc test.
RESULTS
Generating and Testing an Initial FFA4 Receptor Model and
Selecting Residues for Mutagenesis—To define the ligand bind-
ing pocket of human FFA4 and to identify specific residues
important for ligand interaction, we employed combinations of
molecular modeling, receptor mutagenesis, and ligand SAR
studies. Previous work defining the mode of binding of
orthosteric agonists to the free fatty acid receptors FFA1–FFA3
has demonstrated that a pair of Arg residues near the top of the
transmembrane (TM) helical bundle, at positions 5.39 and 7.35
(Ballesteros and Weinstein GPCR numbering scheme (23)),
form critical ionic interactions with the carboxylate of both
endogenous fatty acids and various synthetic ligands (24, 25).
Molecular Basis of Ligand Binding to FFA4
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TABLE 1
Potency and efficacy in a-arrestin-2 recruitment assay of aLA, TUG-891, TUG-670, and GW9508 onwild type FFA4 andmutations predicted to
be in close proximity to the ligand binding pocket
NR means no response.
a Primary amino acid residue number with Ballesteros and Weinstein position in parentheses.
b Cell surface expression is shown as a percentage of wild type; total expression is in parentheses.
c pEC50 values with efficacy expressed as a percentage of the wild type aLA response in parentheses.
d (pEC50 mutant)	 (pEC50 WT FFA4). Statistical significance is as follows: *, p 0.05; **, p 0.01; ***, p 0.001.
Molecular Basis of Ligand Binding to FFA4
20348 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 29•JULY 18, 2014
 at G
lasgow
 U
niversity Library on A
ugust 5, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
However, FFA4 is only distantly related to FFA1–FFA3, and
these two positively charged residues are not conserved.
Instead, several studies have implicated a single Arg at position
2.64 (amino acid 99 in the primary sequence) as the critical
residue involved in the interaction between FFA4 and the car-
boxylate of its ligands (12, 26, 27). Based on this key interaction,
we developed models of the FFA4 ligand binding pocket,
including one described previously (11), to predict additional
residues that might be involved in binding to the receptor of
either the endogenous agonist aLA or selected synthetic
ligands. From this, 21 residues predicted to contribute to or to
be in close proximity to the ligand binding pocket were identi-
fied and subjected to Ala replacement (except for R99Q2.64 and
F303H7.35) mutagenesis (Table 1, top).
Assessment of the Initial Mutants—To assess the impact of
the 21 initial mutations, aLA and three synthetic ligands were
chosen for analysis (Fig. 1). These were the potent and selective
FFA4 agonist TUG-891; the analog TUG-670, lacking the
4-methyl and 4-fluoro substituents that enhance potency and
selectivity at FFA4; and GW9508, an FFA1/FFA4 agonist that
has been widely used in FFA4 studies, despite being markedly
selective for FFA1 (5, 8, 12). Because direct ligand binding
assays are not currently available for FFA4, a BRET-based
FFA4--arrestin-2 interaction assay was used as the primary
assay to assess the effect of FFA4 mutations on ligand-receptor
interactions (Table 1). This assay was chosen because the
ligand-stimulated GPCR--arrestin-2 interaction is predicted
to occur in a 1:1:1 (ligand/GPCR/-arrestin-2) molecular ratio,
and therefore ligand potency in this assay is anticipated to pro-
vide a very good surrogate measure of ligand binding affinity
(28). However, to ensure that the identified FFA4 binding
pocket did not reflect a -arrestin-2 biased receptor conforma-
tion, results with key mutants were also confirmed in Ca2
mobilization assays (Table 2) that represent a Gq/11-mediated
FFA4 signaling end point. Comparing the effects of the four test
ligands at wild type FFA4 in the -arrestin-2 and Ca2 assays
(Tables 1 and 2) demonstrated the same rank order of potency in
each assay such that TUG-891 
 TUG-670 
 GW9508 
 aLA;
however, it was apparent that in the Ca2 assay system the mea-
suredpotencyvalues for thecompoundsweregenerally lower than
observed in the-arrestin-2 assay. Initial testing with the-arres-
tin-2 assay indicated that all four ligands were inactive at an
R99Q2.64 mutant of FFA4 (Table 1), suggesting that all appear
likely to bind to the orthosteric site of the receptor.
Analysis of the other 20 initial mutations (Table 1, top) indi-
cated that all were expressed when transfected with total
expression levels ranging between 38 and 106% of wild type
FFA4 levels. Each mutant was also successfully delivered to the
surface of the cell; however, formost the cell surface expression
was lower than the total expression, suggesting that these
mutants did not fold and traffic to the cell surface as efficiently
as the wild type receptor. Despite this, cell surface expression
correlated significantly with -arrestin-2 recruitment response
efficacy (p  0.001), yielding correlation coefficients of 0.79,
0.73, 0.71, and 0.70 for aLA,TUG-891, TUG-670, andGW9508,
respectively (Fig. 2, A–D). Although only weaker correlations
were observed (0.44, 0.58, 0.62, and 0.51, for aLA, TUG-891,
TUG-670, and GW9508, respectively) between total receptor
expression and response efficacy, this was anticipated as the
-arrestin-2 recruitment assay measures only activation of
receptors expressed at the cell surface. The strong correlation
observed between response efficacy and cell surface expression
suggests that the majority of efficacy variations observed
among the mutants result from expression differences and not
because these mutations alter the ability of FFA4 to be acti-
vated. Importantly, although variations in ligand efficacy were
associated withmutant expression levels, this should not be the
case for ligand potency, due to the 1:1:1 ratio of ligand/recep-
tor/-arrestin-2. In accordance with this, the fact that
increased -arrestin-2 efficacy was observed for the F88A2.53
mutant, which shows substantially increased cell surface
expression compared with wild type, strongly suggests that no
receptor reserve is present to affect the observed potency in this
assay even at the highest expression levels used in this study.
FIGURE1.Structuresandpotenciesof ligandsused in this studyathuman
FFA4 and FFA1. Potencies were determined using the -arrestin-2 recruit-
ment assay.
TABLE 2
Potency of aLA, TUG-891, TUG-670, and GW9508 on wild type FFA4
and selected mutants in a Ca2mobilization assay
NR means no response.
a (pEC50 mutant)	 (pEC50WT FFA4). Statistical significance is as follows: *,
p 0.05; **, p 0.01; ***, p 0.001.
Molecular Basis of Ligand Binding to FFA4
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Examination of the outcomes of such -arrestin-2 recruit-
ment and interaction studies revealed that mutation of each
of five aromatic residues, W104A, F115A3.29, F211A5.42,
W277A6.48, and F304A7.36, eliminated response to all four
ligands (Table 1). Furthermore, mutation of an additional aro-
matic residue Phe-3037.35 to His resulted in a significant (10-
FIGURE 2. Cell surface expression is correlated with -arrestin-2 response efficacy for FFA4 mutants. Correlation plots of receptor--arrestin-2 BRET
response efficacy versus measured cell surface expression are shown for aLA (A), TUG-891 (B), TUG-670 (C), and GW9508 (D). Mutants that gave no ligand-
mediated response were excluded from these analyses. Correlation coefficients are also shown.
FIGURE 3. GW9508 has a distinct mode of binding compared with aLA, TUG-891, and TUG-670. Ca2 assays show the effect of F88A2.53 and F311A7.43
mutations on the potency of aLA (A), TUG-891 (B), TUG-670 (C), and GW9508 (D). These assays demonstrate that although F88A2.53 shows reduced potency for
all ligands except GW9508, F311A7.43 in contrast displays reduced potency only for GW9508. The binding pose of GW9508 compared with aLA, TUG-891, and
TUG-670 is shown in E. GW9508 (green) is positioned at a longer distance (3.3 Å) from Phe-88 than aLA (2.5 Å), TUG-891 (2.4 Å), and TUG-670 (2.7 Å) (all blue)
when docked in this model, in agreement with the lack of effect for the F88A2.53 mutation on this ligand.
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fold) loss of potency to all four ligands. Expression levels of each
of these Ala mutants, and to a lesser extent the F303H7.35
mutant, were reduced. However, these levels were similar to
those observed with several other mutants that did produce
-arrestin-2 recruitment responses, suggesting that the lack of
response represents reduced ligand interaction with FFA4 and
not simply reduced mutant expression. To further confirm the
importance of these residues, stable Flp-InTMT-RExTM293 cell
lines able to express each of these five mutants were also gen-
erated and tested in Ca2 assays (Table 2). These experiments
demonstrated that each compound was also inactive at these
mutants in the Ca2 assay, with the only exception being a low
potency response observed at F304A7.36 with TUG-891 only
(Table 2). Because the Ca2 assay is predicted to be more sen-
sitive at lower receptor expression levels due to the amplifica-
tion of itsmeasured response, the lack of responses in this assay
strongly supports key roles for these residues in the binding of
all four ligands to FFA4. In contrast to the six mutations above
that affected the potency of all ligands, five of the initial muta-
tions, L94A2.59,M118A3.32, T195A, I197A, andV307A7.39, were
found to have no significant effect on the potency of any of the
four ligands tested (Table 1).
As well as the mutations that produced global effects on all
ligands tested, ligand-specific effects were also observed within
the initial set ofmutants. Of particular interest, a group of three
mutants, T119A3.33, N215A5.46, and I280A6.51, significantly
reduced the potency of the two ortho-biphenyl compounds,
TUG-891 and TUG-670, while yielding only modest and non-
significant reductions in potency for GW9508 and not altering
the potency of aLA at all when tested in the -arrestin-2 assay.
The T119A3.33 and N215A5.46 mutations were also assessed
in the Ca2 assay (Table 2), which confirmed that these muta-
tions negatively affected the potency ofTUG-891 andTUG-670
but not aLA when measured at this end point. However, unlike
in the -arrestin-2 interaction assay where the effect of these
mutants did not reach statistical significance, in the Ca2 assay
bothN215A5.46 (p 0.05) and T119A3.33 (p 0.001) produced
significant reductions in potency for GW9508 compared with
wild type FFA4. Together, these results suggest that the
T119A3.33, N215A5.46, and I280A6.51 residues are likely critical
in forming the binding pocket for the ortho-biphenyl fragment
and, perhaps to a lesser degree, the pocket for GW9508. There
was also a single mutant, I281A6.52, that displayed increased
ligand potency in the -arrestin-2 assay however, interestingly,
only for TUG-670 and GW9508. This result was again con-
firmed in the Ca2 assay, also showing significantly increased
potency for TUG-670 (p  0.001) and GW9508 (p  0.05) at
I281A6.52 but not for TUG-891 and aLA (Table 2). That this
mutation enhanced the potency of TUG-670, but not TUG-
891, suggested the residuemight be in close proximity to either
FIGURE 4.Orthosteric binding site of FFA4 in complexwith aLA, TUG-891, TUG-670, andGW9508. The binding poses of aLA (A), TUG-891 (B), TUG-670 (C),
and GW9508 (D) are shown with the side chains of all residues that significantly affect potency when mutated to Ala.
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the methyl- or fluoro-substituents present in TUG-891 but not
TUG-670.
Generation of a Refined FFA4-binding Site Model—Based on
results with the initial set of 21mutations, a refined binding site
model was constructed to identify additional residues poten-
tially involved in ligand binding to FFA4. As all currently
described FFA4 ligands are agonists, we aimed at constructing a
model that represented the active receptor conformation.
Thus, the crystal structure of the nanobody-stabilized 2-adre-
noreceptor in its active state was chosen as a template for con-
struction of the model. The ligands were docked with flexible
binding site residues using the induced fit docking protocol
implemented in the Schro¨dinger Suite. This produced ligand-
receptor complexes with the carboxylate interacting with Arg-
992.64 without manual intervention, although a constraint was
later used at this position to minimize the number of uninter-
esting poses. aLA and the synthetic ligands docked in a com-
mon binding pocket between TM-2, 3, and 5–7 with the car-
boxylic acid anchored to Arg-992.64 in TM-2. Central to this
model were the four aromatic residues F115A3.29, F211A5.42,
W277A6.48, and F304A7.36 within the TMs that, whenmutated,
essentially eliminated responsiveness to each ligand tested.
These were predicted to line a hydrophobic ligand binding
pocket. A further residue, Trp-104, that ablated function of
each ligandwhen it wasmutated to alanine is located in the first
extracellular loop (ECL1) and was predicted in the refined
model to form a hydrogen bond between the indole nitrogen of
its side chain and the carboxylate of the ligands. Using this
model, an additional seven residues of interest in the receptor
were identified, each mutated to Ala, and tested in the -arres-
tin-2 interaction assay (and in some cases the Ca2 assay) with
aLA, TUG-891, TUG-670, and GW9508 (Table 1, bottom).
One of these mutants, W207A5.38, resulted in complete loss of
function to all ligands, while the T310A7.42 mutant also pro-
duced a greater than 10-fold reduction in potency to each
ligand. The F88A2.53 mutant gave a 10-fold reduction in
potency for aLA, TUG-891, and TUG-670 but did not signifi-
cantly affect GW9508, which together with the selective effect
of F311A7.43 on GW9508 suggests an incomplete overlap with
the ortho-biphenyl poses. The effects of these two mutants on
GW9508 were also confirmed in the Ca2 assay (Table 2),
where again F88A2.53 significantly reduced potency to aLA,
TUG-891, and TUG-670, but not GW9508, while F311A7.43
significantly reduced potency only to GW9508 but not the
other ligands (Fig. 3, A–D). These observations are consistent
with the predicted binding pose of GW9508 in the model, sug-
gesting that this ligand is positioned further away from Phe-88
than the other ligands (Fig. 3C). The I126A3.40 mutant selec-
tively affected the two ortho-biphenyl compounds TUG-891
and TUG-670, while V212A5.43 reduced potency of TUG-891
only, and both of these effects were also observed in the Ca2
assay (Table 2). I201A and F216A5.47 did not result in statisti-
cally significant changes in ligand potency. Apart from Trp-
2075.38 for all four ligands and Trp-1002.65 and Leu-1143.28 for
TUG-891, all mutations that gave a statistically significant
change in potency were predicted to be in direct contact with
the ligands (Fig. 4,A–D). The effect of Trp-2075.38 appears to be
through stackingwith Phe-2115.42, positioning this residue cor-
rectly toward the general binding pocket.
To validate the refinedmodel, we docked aLA, GW9508, and
10 ortho-biphenyl ligands (Table 3) using the extra precision
induced fit protocol and calculated relative binding energies by
MM-GBSA simulation (see under “Experimental Procedures”).
This resulted in good correlation (r  	0.84) between pEC50
values and calculated relative binding energies (Table 3), indi-
cating that themodel explains the binding of the ligands excep-
tionally well (29). To further test and cross-validate the refined
model, we introduced in silicomutations to generate individual
binding site models of mutants. Binding energies of aLA, TUG-
891, TUG-670, and GW9508 in complex with selected mutant
models were calculated usingMM-GBSA simulation (Table 4).
Relative binding energies were generally in very good agree-
ment with the trends observed from the BRET assay (Fig. 5,
A–D). Considerable loss of binding energy for all four agonists
was observed for models incorporating the R99Q2.64, W104A,
F115A3.29, F211A5.42, W277A6.48, F303H7.35, F304A7.36, and
T310A7.42mutations comparedwith thewild type FFA4model,
in good agreement with the experimental results. Mutations
that resulted in low or nonsignificant reductions in potency in
the BRET assay (M118A3.32, T119A3.33, R178Q, I197A, and
V212A5.43) were also generally (except M118A3.32 for aLA and
TUG-670) found to have only small effects on calculated bind-
ing energy. The predicted effects of N215A5.46 and I280A6.51
were satisfactory for the synthetic ligands, but not for aLA,
where large negative and positive effects, respectively, were
found in the model, compared with nonsignificant experimen-
tal effects, suggesting that the pose of the lower part of the fatty
acid tail is less accurate. Notably, the specific effect of the
TABLE 3
Calculated binding energy and -arrestin-2 recruitment potency of
various ortho-biphenyl compounds
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F88A2.53 mutation on aLA, TUG-891, and TUG-670, but not
GW9508, was reflected accurately in the models. Finally,
although the predicted binding energies for the I281A6.52
mutant suggestedTUG-891 should lose potency at thismutant,
which was not observed experimentally, the relative effects of
modifying the steric bulk at Ile-2816.52 through theAla, Val, and
Phe mutations were accurately predicted (see below).
The F303H7.35mutation resulted in a significant loss of activ-
ity for all ligands. This was reflected in themodeling by a loss of
binding energy of the docked ligands in themutant binding site
model as a result of a shift of the hydrophobic phenylpropionate
moiety away from the more polar His-3037.35. Similar loss of
binding energy was observed upon docking of the ligands into
models of the F88A2.53 andT310A7.42mutants. F88A2.53 affects
binding energy of TUG-891 and TUG-670 to a larger extent as
compared with aLA and GW9508, whereas the T310A7.42
mutation affects all the ligands approximately to the same
degree. In the cases of T119A3.33, N215A5.46, and I280A6.51, a
loss in binding energy was observed only for the ortho-biphenyl
compounds TUG-670 and TUG-891 but not for aLA or
GW9508. Docking in the mutant model V212A5.43 caused a
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FIGURE 5. Comparison of calculated binding energies and experimental potencies obtained for various ligands and mutant forms of FFA4. Relative
effects of mutations on binding energies predicted from docking in mutant receptor models (G (kcal/mol), red bars, scale on left side) and experimentally
determined potency (pEC50, green bars, scale on right side, inactive in blue) for aLA (A) TUG-891 (B), TUG-670 (C), and GW9508 (D).
TABLE 4
Calculated binding energies for TUG-891, TUG-670, and GW9508 in
models with key residues mutated
a G is the difference: (Gbind)mutant	 (Gbind)WT.
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moderate loss in binding energy of TUG-891, but it did not
affect the other ligands, in agreement with the experimental
results.
The model suggests combined ionic and hydrogen bond
interactions between the ligand carboxylate and the established
anchor residue Arg-992.64 and in addition a hydrogen bond
interaction with Trp-104 in ECL1. The phenylpropionate moi-
ety of the synthetic ligands interacts with Phe-3037.35 and Phe-
3047.36 on the top side andwith Phe-1153.29 on the bottom side.
The ortho-biphenyl part is incorporated into a narrow hydro-
phobic binding pocket lined by Phe-882.53, Thr-1193.33, Gly-
1223.36, Trp-2776.48, Thr-3107.42, Asn-2155.46, Val-2125.43, Phe-
2115.42, Ile-2816.52, and Ile-2806.51 (Fig. 6). Supporting this
model of TUG-891 binding is the observation that although the
Alamutations of nine of these 10 residues (Ile-2816.52 being the
one exception) resulted in significant loss of potency of TUG-
891, only four significantly lost potency to aLAandonly three to
GW9508. Indeed, docking ofGW9508 to themodel suggested a
somewhat different mode of interaction within the hydropho-
bic binding pocket. In particular there appeared to be a critical
- stacking interaction with Phe-3117.43 not present with
either TUG-891 or TUG-670 (Fig. 4D). This is consistent with
the observation that the F311A7.43 mutant displayed reduced
potency in both -arrestin-2 and Ca2 assays to GW9508 but
not to any of the other ligands tested (Tables 1 and 2).
Defining the Role of Isoleucine 281—To examine the pre-
dicted mode of binding of TUG-891 in more detail, we next
looked at the one mutation predicted to be in the ortho-biphe-
nyl binding pocket that did not affect the potency of TUG-891,
i.e. I281A6.52. In the model this residue is located at the top of
the ortho-biphenyl pocket and is in close proximity to the ter-
minal methyl group of TUG-891. Interestingly, although this
mutation did not alter the potency of TUG-891, it did produce
an increase in potency of TUG-670 in both -arrestin-2 and
Ca2 assays (Tables 1 and 2). Based on the modeled binding
pose, we hypothesized that the difference between TUG-891
and TUG-670 at this mutant might result from the presence of
the terminal methyl in TUG-891, which is absent in TUG-670.
To test this hypothesis, we examined the potency of various
ortho-biphenyl analogs at the wild type receptor and the
I281A6.52 mutant in the -arrestin-2 assay (Table 5). It was
apparent that compounds with a 4-methyl substituent did not
show gain in potency at the I281A6.52 mutant, whereas each
compound without such a substituent displayed at least a
10-fold increase in potency. Indeed, for compoundswith termi-
nal ortho- ormeta-methyl groups, there was a 50-fold increase
in potency at the I281A6.52 mutant compared with wild type
FFA4. To further demonstrate that the terminal methyl of
TUG-891 is in close proximity to Ile-2816.52, we generated and
tested in the -arrestin-2 assay additional Phe and Val muta-
tions of this residue with ortho-biphenyl compounds TUG-891
(Fig. 7A), TUG-670 (Fig. 7B), TUG-854 (Fig. 7C), and TUG-827
(Fig. 7D and Table 5). Interestingly, a common trend was again
observed, where in this case the I281F6.52 mutant reduced the
potency of compounds containing the terminal 4-methyl
(TUG-891 and TUG-827), although this alteration had no sig-
nificant inhibiting or enhancing effect on compounds lacking
this methyl group (TUG-670 and TUG-854). In contrast, the
I281V6.52 mutation resulted in increased potency to all four
ligands, although the potency of TUG-670 andTUG-854 at this
mutant was not as high as that observed for these compounds
with the I281A6.52 mutation. Together these results clearly
demonstrate thatVal at position 2816.52 results in optimal bind-
ing of compounds containing the terminal methyl, whereas Ala
is optimal for compounds lacking this substituent.
Although these experimental results clearly indicate that Ile-
2816.52 interacts with the terminal methyl of TUG-891, it was
still somewhat surprising that the observed effect for the
I281A6.52 mutant was a gain in potency for compounds lacking
this substituent. To examine why this might be the case, we
incorporated the Ala mutation into the FFA4-binding site
model and explored how this affected the binding pose and
predicted binding energy of TUG-891, as well as other ortho-
biphenyl SAR variants (Table 6). Interestingly, changes in pre-
dicted binding energies for these ligands calculated using the
model containing Ala-2816.52 compared with those calculated
FIGURE 6. ortho-Biphenyl binding pocket of FFA4. The binding pocket
formed by Phe-882.53, Thr-1193.33, Gly-1223.36, Trp-2776.48, Thr-3107.42, Asn-
2155.46, Val-2125.43, Phe-2115.42, Ile-2806.51, and Ile-2816.52. Residues are
shown in orange, and TUG-891 is shown in green.
TABLE 5
Effect of Ile-2816.52mutations on-arrestin-2 recruitment potency for
various ortho-biphenyl compounds
NDmeans not determined.
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using wild type receptor correlated extremely highly (r 
	0.97) with the experimental potency changes at this mutant
(Table 6). Thus, although the model predicted loss of potency
for the 4-methyl analogs TUG-891 and TUG-827 and a more
moderate gain of potency than what was observed for the other
ligands, the relative changes in calculated binding energy were
accurately predicted. Detailed examination of the docking pose
in the model incorporating I281A6.52 suggests that this muta-
tion allows the top ring of the ortho-biphenyl system to shift
toward a hydrophobic binding pocket lined by Ile-2806.51, Ala-
2816.52, and Trp-2776.48, which leads to better ligand packing
and increased potency. This shift in binding pose was restricted
for TUG-891 (Fig. 8A) and TUG-827 (Fig. 8B) by their
4-methyl substituents, but it was clearly observed for com-
pounds lacking this substituent TUG-670 (Fig. 8C) and TUG-
854 (Fig. 8D), thus accounting for the observation that TUG-
891 and TUG-827 did not experimentally gain potency at the
I281A6.52 mutant. Indeed, the 4-methyl groups of TUG-891
and TUG-827 were predicted to be in direct contact with Val-
2125.43 and therefore unable to move further into the binding
pocket when it was widened by the I281A5.43 mutation (Fig. 9).
This prediction is in good agreement with experimental data
obtained in both -arrestin-2 and Ca2 assays demonstrating
that V212A5.43 loses potency to the 4-methyl containingTUG-
891 but not to TUG-670 (Tables 1 and 2).
DISCUSSION
FFA4 is a GPCR activated by LCFAs that has garnered signif-
icant attention in recent years as a novel therapeutic target for
the treatment of metabolic disease (1, 2, 30). Despite this inter-
est, a lack of potent and selective ligands for the receptor has
limited its development. Although we recently reported TUG-
891 as a potent and selective FFA4 agonist (11), andweused this
compound to begin elucidating the potential of this receptor
(12), there is clearly still a need for better FFA4 ligands. To
facilitate this, this work has conducted the first extensive
mutagenesis of FFA4 to define how TUG-891 and other FFA4
agonists bind to this receptor.
Through this, a well validated homology model of FFA4 was
constructed that provides a rationale for the molecular basis of
ligand interaction with this receptor. Homology modeling has
become common practice in structure-based GPCR drug dis-
covery, primarily due to the difficulty obtaining detailed crystal
structures of this family of receptors. Although such models
have proven useful with other receptors (13, 14), it must also be
noted that their accuracy is sometimes questionable. The best
example of this being that before the crystal structure of theA2A
adenosine receptor bound to its antagonist ligand ZM241385
was published (31), researchers were asked to submit models of
this interaction, which were then compared with the obtained
FIGURE 7. Effect of Ala, Phe, and Val mutations at position Ile-2816.52 of FFA4 on the potency of ortho-biphenyl compounds. Concentration-response
curves for TUG-891 (A), TUG-670 (B), TUG-854 (C), and TUG-827 (D) at each of wild type (circles), I281A6.52 (squares), I281F6.52 (triangles), and I281V6.52 (inverted
triangle) FFA4 in the -arrestin-2 BRET assay.
TABLE 6
Calculatedbindingenergy forortho-biphenyl compoundsat I281A6.52
mutant
a G is the difference: (G I281A6.52)	 (GWT FFA4).
b  pEC50 is the difference: (pEC50 at I281A6.52)	 (pEC50 at WT FFA4).
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crystal structure (32). Of the over 150 models that were exam-
ined in this study, very few successfully predicted both the
ligand position and ligand-receptor contacts. This highlights
the need for good experimental data, as we have provided
through both mutational and SAR studies to validate a homol-
ogy model.
As this is the firstdetailedexaminationof theFFA4-bindingsite,
it is also interesting tocompare ligandbindingwith this receptor to
how ligands interact with the other LCFA receptor, FFA1, espe-
cially because the two receptors are found to recognize the same
chemical structures and that obtaining selective compounds
indeed can be challenging (11). Previous studies have examined
LCFAs and GW9508 binding to FFA1, finding in particular the
ligand’s carboxylate interacted with Arg-5.39, Asn-6.55, and Arg-
7.35, whereas His-3.32, Tyr-3.37, and His-4.56 appeared to form
aromatic or hydrophobic interactions specifically with GW9508
(24, 33). Interestingly, none of these sites are conserved in FFA4,
and indeed althoughmutations at positions 6.55 and 7.35 of FFA4
did affect ligand binding, in FFA4 these residues are hydrophobic
and therefore do not appear to contribute to ligand binding in the
same way as they do in FFA1.
Interestingly, a recent examination of currently available
GPCR crystal structures identified trends in the key residues
involved in ligand interaction among receptors activated by the
same ligand class (15). Although the S1P1 receptor is currently
the only lipid receptor for which a structure is available (34), it
must be pointed out thatmany of the sites we identify as impor-
FIGURE 8. Effects of the I281A6.52 mutation on biphenyl ligands with andwithout the 4-methyl substituent. The poses of TUG-891 (A) and TUG-827 (B)
are minimally affected by the I281A6.52 mutation (0.79 and 0.82 Å, respectively), whereas TUG-670 (C) and TUG-804 (D) shift further into the pocket (1.59 and
1.68Å, respectively). Ala-2816.52 shownasblue spheresoverlappedby Ile-2816.52 shownas transparent cyan spheres. The structuresdocked in thewild typeFFA4
model are cyan, and structures docked in the I281A6.52 mutant model are blue.
FIGURE 9. Terminal 4-methyl group of TUG-891 is in direct contact with
Val-212. Compounds TUG-670 (left) and TUG-891 (right) docked in the wild
type FFA4. Phe-2115.42, Val-2125.43, Ile-2806.51 (not shown), and Ile-2816.52
form a pocket around the terminal ring of the biphenyl system.
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tant for ligand binding to FFA4 are the same as those identified
as important in this structure. In particular, residues at 2.64 (Ser
in S1P1 and Arg in FFA4, both engage in hydrogen bond inter-
actions with the negatively charged group), 5.42 (Phe in both
receptors), 6.48 (Trp in both receptors), 6.55 (Leu in S1P1 and
Ile in FFA4), 6.52 (Phe in S1P1 and Ile in FFA4), and 7.39 (Leu in
S1P1 and Val in FFA4) were each involved in hydrophobic
interactions between the receptor and their respective ligands.
Although this perhaps suggests that despite the limited homol-
ogy between these two receptors their lipid ligands may still
interact in a similar manner, clearly this will need to be
addressed in more detail in the future.
Finally, it was also interesting to note that there was a clear
trend among the four FFA4 agonists tested across all mutations
in that the more potent ligands tended to be affected by more
mutations. Specifically, although the potency of TUG-891 was
altered by mutation at 18 of the 27 residues tested, TUG-670
was only affected by 15, GW9508 by 14, and aLA only by 11.
This appears consistent with the prediction that the more
potent compounds form more contacts with the receptor, and
indeed it is similar to what was previously observed with
GW9508 compared with aLA at FFA1 (33).
In recent times the concept of biased signaling of GPCRs,
whereby an agonist ligandmay selectively activate one signaling
pathway over others emanating from the same receptor (for
example -arrestin-mediated versus G protein-mediated), has
received substantial interest for its potential to yield therapeu-
tics with improved efficacy and reduced adverse effects (35–
37). Indeed, given that the anti-inflammatory effects of FFA4
are reported to be -arrestin-2-mediated (4), and the effects on
GLP-1 are likely to be Gq/11-mediated (3, 12), we have recently
developed a G protein-biased form of the FFA4 receptor (38) to
help elucidate the potential of biased FFA4 agonists. Consider-
ing this, it was important to determine whether the receptor
model that was generated in this study based predominantly on
results generated in the -arrestin-2 interaction assay also
translated to a G protein-mediated Ca2 end point. This was
indeed the case, where each key mutant observed to affect
ligand potency in the -arrestin-2 assay also produced a similar
effect in the Ca2 assay. Although this suggests that the model
suitably describes a binding pocket that is not biased to favor
one of these pathways over the other, this is probably not sur-
prising as we have previously found the ligands studied herein
to display little functional bias (11). Indeed, given the general
chemical similarity among all currently described FFA4 ligands,
comprising a negatively charged carboxylic acid headgroup and
an extended hydrophobic tail, there is likely a need for
increased chemical diversity among FFA4 agonist ligands
before compounds with true bias at this receptor may be
identified.
In this work, we have provided the first detailed examination
of ligand binding to FFA4. In doing so, we have demonstrated
several key residues that whenmutated affect ligand function at
this receptor, and we have used this information to refine a
homology model of the receptor. By using SAR studies in com-
bination with our mutational approach, we have been able to
provide strong validation of the mode of ligand binding
described in the model. Notably, the model was able to predict
the effect of variations or substitution in the biphenyl part of the
compound series on the activity on the wild type FFA4 and
produced a high correlation between the two parameters.
Docking in models of each of 20 mutants also produced results
that in the majority of cases predicted the experimentally
observed effects. Taken together, this should provide invalu-
able information to guide future in silico drug discovery at the
FFA4 receptor.
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